000050147 000__ 02467nam\a2200397\i\4500
000050147 001__ 50147
000050147 003__ SzGeWIPO
000050147 005__ 20241024004425.0
000050147 006__ m    eo  d        
000050147 007__ cr bn |||m|||a
000050147 008__ 241007s2024\\\\enk\\\\\o\\\\\000\0\eng\d
000050147 0247_ $$a10.1093/grurint/ikae091$$2doi
000050147 035__ $$a(OCoLC)1463455364
000050147 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000050147 041__ $$aeng
000050147 24500 $$aNew Progress in China’s Anti-Monopoly Investigation into the Pharmaceutical Industry – :$$bComment on the Injectable Polymyxin B Sulfate Case.
000050147 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2024.
000050147 300__ $$a1 online resource (pages  858-864)
000050147 336__ $$atext$$2rdacontent
000050147 337__ $$acomputer$$2rdamedia
000050147 338__ $$aonline resource$$bcr$$2rdacarrier
000050147 4901_ $$aGRUR International,$$x2632-8550 ;$$v73, 9, 2024
000050147 520__ $$aChina’s competition authorities imposed a record penalty in the pharmaceutical sector against four pharmaceutical companies for jointly abusing their market dominance and engaging in excessive pricing behavior. This incident caused widespread concern and controversy, and has raised questions about the fairness and transparency of the pharmaceutical industry. From the perspective of antitrust enforcement, the administrative penalty decision has significant value for discussion in several aspects, including the identification of the subjects engaged in joint abuse of market dominance, the delineation of the relevant market, the determination of excessive prices, the imposition of penalties, and subsequent corrective measures. Furthermore, the coordination and cooperation between the competition authorities and the health security authorities in this case also merit discussion. This opinion provides an overview of the grounds of the decision and a detailed analysis in the context of China’s anti-monopoly regulations and guidelines for the pharmaceutical sector.
000050147 542__ $$fhttps://academic.oup.com/grurint/article/72/3/231/6998505
000050147 588__ $$aCrossref
000050147 590__ $$aPublished online: 18-Jul-24
000050147 650_4 $$aMonopolistic competition.
000050147 650_0 $$aPharmaceutical policy.
000050147 650_4 $$aCompetition law.
000050147 650_0 $$aCopyright.
000050147 7001_ $$aWei, De,$$eauthor.
000050147 7731_ $$tGRUR International$$wGRUR
000050147 830_0 $$aGRUR International ;$$v73, 9, 2024,$$x2632-8550.
000050147 85641 $$uhttps://doi.org/10.1093/grurint/ikae091$$yonline version
000050147 904__ $$aJournal article
000050147 980__ $$aGRUR